International Myeloma Society 2022 Annual Meeting

Belantamab Mafodotin Yields Good Response Rate in Patients With Relapsed, Refractory Multiple Myeloma

Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma

Lower Risk of Smoldering Multiple Myeloma Progression Among African Americans

Researchers sought to determine whether there were differences in rates of progression of smoldering multiple myeloma in African American patients.

D-Rd Appears to Improve Long-Term Outcomes in Newly Diagnosed, Transplant-Ineligible Myeloma

Researchers sought to determine whether adding daratumumab to lenalidomide and dexamethasone would improve outcomes in patients with newly diagnosed, transplant-ineligible MM.

Quadruplet Therapy Shows Promising Results as Salvage Therapy for Relapsed/Refractory Multiple Myeloma

Researchers sought to determine whether adding ixazomib to daratumumab, pomalidomide, and dexamethasone would be a treatment option in patients with R/R MM.